7Mixed Chimerism after Allogeneic Stem Cell Transplantation - Focus on Double Cord Blood Transplantation
- Corresponding Author:
- Michael Uhlin
Centre for Allogeneic Stem Cell Transplantation B87
Karolinska University Hospital Huddinge, SE-14186 Stockholm
E-mail: [email protected]
Received Date: January 16, 2012; Accepted Date: February 03, 2012; Published Date: February 09, 2012
Citation: Jens G, Arwen S, Emma W, Jonas M, Michael U (2012) Mixed Chimerism after Allogeneic Stem Cell Transplantation – Focus on Double Cord Blood Transplantation. J Blood Disord Transfus S1:006. doi: 10.4172/2155-9864.S1-006
Copyright: © 2012 Jens G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Allogeneic hematopoietic Stem Cell Transplantation (ASCT) is well established as a curative treatment for many hematological malignancies and non-malignant disorders. The aim of ASCT in these diseases is to achieve sustained donor engraftment to fight leukemic cells in malignant disease, improve hematopoietic function, provide immune competence or normalize enzyme deficiency. Peripheral blood or bone marrow is commonly used to monitor engraftment after ASCT. The presence of mixed donor/recipient chimerism after transplantation, donor/donor chimerism after double cord blood transplantation can be used and interpreted differently based on the initial disease status. In patients with malignant diseases, chimerism is primarily used to detect early relapse but can also indicate threatening rejection. In individuals with non malignant disease, chimerism is merely used to monitor successful engraftment. After double cord blood transplantation, the unique situation with two existing donor immune systems can occur. Most often one of the immune systems rapidly succumbs with one immune system prevailing, but in certain situations mixed donor/donor chimerism can exist for prolonged periods. This review describes the importance of mixed chimerism and the possible interpretation after ASCT in patients with both malignant and non-malignant diseases. It also focuses specifically on the situation and mechanisms donor/ donor chimerism after double cord blood transplantation.